Privacy Statement
This privacy statement discloses the privacy practices and restrictions for the PharmaDerm web site: www.pharmaderm.com.
Information Collection and Use:
PharmaDerm is the sole owner of the information collected through our web site. We do not sell or rent this information to others. PharmaDerm may collect statistical information on visitors to our web site, as well as personal information from users who voluntarily submit information to us.
Links:
This web site may contain links to other sites. Please be aware that PharmaDerm is not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of each and every web site that collects personally identifiable information.
Security:
This application takes every precaution to protect our users' information. When users submit sensitive information via our web site, the information is protected both online and off-line. Information submitted via our web site is encrypted with SSL software. While we use SSL encryption to protect sensitive information online, we also do everything in our power to protect user-information off-line. All of our users' information, not just the sensitive information mentioned above, is restricted in our offices.
Notification of Changes:
If we need to change our privacy policy, we will post the changes on our web site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it.
Important Product Safety Information
VEREGEN® Ointment, 15% is a medicine for skin use only (topical) for the treatment of warts on the outside of the genitals and around the outside of the anus. It is not a treatment for warts in the vagina, cervix, or inside the anus. Your doctor may recommend examination and screening tests (such as a Pap smear) to evaluate these areas.
VEREGEN® has not been evaluated to treat urethral, intra-vaginal, cervical, rectal, or intra-anal human papilloma viral disease and should not be used to treat these conditions. Avoid use of VEREGEN® on open wounds. Do not expose skin that has been treated with VEREGEN® to the sun or ultraviolet light because VEREGEN® has not been tested in these conditions. Safety and efficacy of VEREGEN® have not been established in immunosuppressed or pediatric patients, or pregnant women, or for the treatment of external genital and perianal warts beyond 16 weeks or for multiple treatment courses.
The most common adverse reactions that occurred in more than 20% of patients in studies with VEREGEN® were reactions of the skin and application site. These included reddening of the skin, itching, burning, pain or discomfort, skin ulcers, wearing down of the skin, swelling, hard spots, and rash with blisters.
VEREGEN® (sinecatechins) Ointment Full Prescribing Information
